GeneDx Holdings (WGS) Other Operating Expenses (2022 - 2024)

GeneDx Holdings (WGS) has reported Other Operating Expenses for 3 consecutive years, with $2.6 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Other Operating Expenses fell 20.59% year-over-year to $2.6 million; the TTM figure through Sep 2025 stood at $2.6 million (up 285.59% YoY), while the FY2023 annual figure was -$2.0 million, up 69.0% from the prior year.
• Other Operating Expenses climbed to $2.6 million in Q4 2024 per WGS's latest filing, from -$774000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $3.3 million in Q4 2023 and bottomed at -$2.8 million in Q3 2023.
• Historically, Other Operating Expenses has averaged -$525400.0 across 3 years, with a median of -$924000.0 in 2024.
• On a YoY basis, Other Operating Expenses climbed as much as 306.38% in 2023 and fell as far as 64.64% in 2023.
• GeneDx Holdings' Other Operating Expenses stood at -$1.6 million in 2022, then jumped by 306.38% to $3.3 million in 2023, then declined by 20.59% to $2.6 million in 2024.
• Business Quant data shows WGS's Other Operating Expenses at $2.6 million in Q4 2024, -$774000.0 in Q3 2024, and -$874000.0 in Q2 2024.